EternoGen, a startup developing a botox alternative, raises $1m in series A round from unspecified backers.
University of Missouri-Columbia startup EternoGen, which is commercialising a potential rival to aesthetic beauty treatment botox, has received $1.065m from unspecified backers. In addition, the Columbia-based firm said that it anticipates a further $500k following significant interest from investors. EnternoGen is developing collagen replenishment therapies which could potentially rival the well-established beauty treatment botox, used…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
